54
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Signal Transducer and Activator of  Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for Leukemogenesis

      research-article

      Read this article at

      ScienceOpenPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Signal transducer and activator of transcription (STAT)5 is constitutively activated in BCR/ ABL-expressing cells, but the mechanisms and functional consequences of such activation are unknown. We show here that BCR/ABL induces phosphorylation and activation of STAT5 by a mechanism that requires the BCR/ABL Src homology (SH)2 domain and the proline-rich binding site of the SH3 domain. Upon expression in 32Dcl3 growth factor–dependent myeloid precursor cells, STAT5 activation–deficient BCR/ABL SH3+SH2 domain mutants functioned as tyrosine kinase and activated Ras, but failed to protect from apoptosis induced by withdrawal of interleukin 3 and/or serum and did not induce leukemia in severe combined immunodeficiency mice. In complementation assays, expression of a dominant-active STAT5B mutant (STAT5B-DAM), but not wild-type STAT5B (STAT5B-WT), in 32Dcl3 cells transfected with STAT5 activation–deficient BCR/ABL SH3+SH2 mutants restored protection from apoptosis, stimulated growth factor–independent cell cycle progression, and rescued the leukemogenic potential in mice. Moreover, expression of a dominant-negative STAT5B mutant (STAT5B-DNM) in 32Dcl3 cells transfected with wild-type BCR/ABL inhibited apoptosis resistance, growth factor–independent proliferation, and the leukemogenic potential of these cells. In retrovirally infected mouse bone marrow cells, expression of STAT5B-DNM inhibited BCR/ABL-dependent transformation. Moreover, STAT5B-DAM, but not STAT5B-WT, markedly enhanced the ability of STAT5 activation–defective BCR/ABL SH3+SH2 mutants to induce growth factor–independent colony formation of primary mouse bone marrow progenitor cells. However, STAT5B-DAM did not rescue the growth factor–independent colony formation of kinase-deficient K1172R BCR/ABL or the triple mutant Y177F+R522L+ Y793F BCR/ABL, both of which also fail to activate STAT5. Together, these data demonstrate that STAT5 activation by BCR/ABL is dependent on signaling from more than one domain and document the important role of STAT5-regulated pathways in BCR/ABL leukemogenesis.

          Related collections

          Most cited references83

          • Record: found
          • Abstract: found
          • Article: not found

          Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6.

          The STAT family of proteins carries out a dual function: signal transduction and activation of transcription. A new family member, Stat3, becomes activated through phosphorylation on tyrosine as a DNA binding protein in response to epidermal growth factor (EGF) and interleukin-6 (IL-6) but not interferon gamma (IFN-gamma). It is likely that this phosphoprotein forms homodimers as well as heterodimers with the first described member of the STAT family, Stat91 (renamed Stat1 alpha), which is activated by the IFNs and EGF. Differential activation of different STAT proteins in response to different ligands should help to explain specificity in nuclear signaling from the cell surface.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

            Oncogenic activation of the proto-oncogene c-abl in human leukemias occurs as a result of the addition of exons from the gene bcr and truncation of the first abl exon. Analysis of tyrosine kinase activity and quantitative measurement of transformation potency in a single-step assay indicate that variation in bcr exon contribution results in a functional difference between p210bcr-abl and p185bcr-abl proteins. Thus, foreign upstream sequences are important in the deregulation of the kinase activity of the abl product, and the extent of deregulation correlates with the pathological effects of the bcr-abl proteins.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              STATs: signal transducers and activators of transcription.

              J N Ihle (1996)
                Bookmark

                Author and article information

                Journal
                J Exp Med
                The Journal of Experimental Medicine
                The Rockefeller University Press
                0022-1007
                1540-9538
                19 April 1999
                : 189
                : 8
                : 1229-1242
                Affiliations
                From the [* ]Department of Microbiology and Immunology, Kimmel Cancer Center,  Thomas Jefferson University, Philadelphia, Pennsylvania 19107; the []Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; and the [§ ]Department of Hematopoietic Factors, Institute of Medical Science, University of  Tokyo, Tokyo 108, Japan
                Author notes

                Address correspondence to Tomasz Skorski, Department of Microbiology and Immunology, Kimmel Cancer Institute, Jefferson Alumni Hall Rm. 372, 1020 Locust St., Philadelphia, PA 19107. Phone: 215-503-0438; Fax: 215-923-7144; E-mail: tomasz.skorski@ 123456mail.tju.edu , or to Bruno Calabretta, Kimmel Cancer Institute, BLSB 630, 233 South 10th St., Philadelphia, PA 19107. Phone: 215-503-4523; Fax: 215-923-0249; E-mail: b_calabretta@ 123456hendrix.lac.tju.edu

                Article
                2193033
                10209040
                7f64d541-4f85-48e2-a41a-94bbcbc3463f
                Copyright @ 1999
                History
                : 15 October 1998
                : 13 January 1999
                Categories
                Articles

                Medicine
                oncoprotein,domains,cooperation,transformation,leukemia
                Medicine
                oncoprotein, domains, cooperation, transformation, leukemia

                Comments

                Comment on this article